Abstract
Anticoagulants can complicate the approach to the management of patients undergoing operative interventions. We review new anticoagulants that have been introduced recently to the market or that are undergoing investigations for treatment of nonvalvular atrial fibrillation and venous thromboembolism prophylaxis: Dabigatran, rivaroxaban, apixiban, and edoxaban.
Copyright © 2013 Mosby, Inc. All rights reserved.
MeSH terms
-
Anticoagulants / adverse effects*
-
Anticoagulants / antagonists & inhibitors
-
Anticoagulants / pharmacokinetics
-
Anticoagulants / pharmacology
-
Atrial Fibrillation / drug therapy
-
Benzimidazoles / adverse effects
-
Benzimidazoles / pharmacokinetics
-
Benzimidazoles / pharmacology
-
Blood Loss, Surgical
-
Clinical Trials as Topic
-
Dabigatran
-
Humans
-
Morpholines / adverse effects
-
Morpholines / pharmacokinetics
-
Morpholines / pharmacology
-
Pyrazoles / adverse effects
-
Pyrazoles / pharmacokinetics
-
Pyrazoles / pharmacology
-
Pyridines / adverse effects
-
Pyridines / pharmacokinetics
-
Pyridines / pharmacology
-
Pyridones / adverse effects
-
Pyridones / pharmacokinetics
-
Pyridones / pharmacology
-
Rivaroxaban
-
Stroke / prevention & control
-
Surgical Procedures, Operative / adverse effects*
-
Thiazoles / adverse effects
-
Thiazoles / pharmacokinetics
-
Thiazoles / pharmacology
-
Thiophenes / adverse effects
-
Thiophenes / pharmacokinetics
-
Thiophenes / pharmacology
-
Venous Thromboembolism / prevention & control
-
Warfarin / adverse effects
-
beta-Alanine / adverse effects
-
beta-Alanine / analogs & derivatives
-
beta-Alanine / pharmacokinetics
-
beta-Alanine / pharmacology
Substances
-
Anticoagulants
-
Benzimidazoles
-
Morpholines
-
Pyrazoles
-
Pyridines
-
Pyridones
-
Thiazoles
-
Thiophenes
-
beta-Alanine
-
apixaban
-
Warfarin
-
Rivaroxaban
-
Dabigatran
-
edoxaban